Phase 2 study of MYMD-1 for treatment of rheumatoid arthritis
Latest Information Update: 30 Jul 2024
At a glance
- Drugs Isomyosamine (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
Most Recent Events
- 22 Jul 2024 According to TNF Pharmaceuticals media release, MyMD Pharmaceuticals, Inc changed its name to TNF Pharmaceuticals, Inc.
- 06 Dec 2023 According to a MyMD Pharmaceuticals media release, the Investigational New Drug (IND) application for a Phase 2 clinical trial of oral MYMD-1 as a treatment for rheumatoid arthritis (RA) was recently cleared by the U.S. Food and Drug Administration (FDA).
- 06 Dec 2023 According to a MyMD Pharmaceuticals media release, Company plans to initiate this trial in the first quarter of 2024.